Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 34 matches for

The collective force of cancer research, outreach and care across the city of Oxford, translating discoveries into better care for cancer patients.

Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments

Scientists from the University of Oxford's MRC Weatherall Institute of Molecular Medicine and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow. This technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual cancer patients.

Funding to develop a new device for breast cancer detection

Professor Jason Davis has been awarded a Cancer Research UK Early Detection and Diagnosis Primer Award to develop a single-step, ultra-sensitive device for detecting breast cancer cells in the blood.

New study shows MRI-guided radiotherapy could double survival rates for people with inoperable pancreatic cancer

A study in partnership with GenesisCare has found high dose ablative radiotherapy doubles the chance of living at least two years after diagnosis.

How Oxford has shaped cancer science

As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Tamsyn Clark awarded Raven prize by British Association of Surgical Oncology

DPhil in Cancer Science student Tamsyn Clarke is investigating the potential of normothermic machine perfusion to study and enable the targeted delivery of cancer therapeutics to human organs.

Advancing radiotherapy technology through clinical trials

Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS

A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.

The next step in personalised cancer medicine

Botnar Research Centre researchers have developed standalone long-read sequencing of single cells technology that could open new avenues into the causes of diseases like cancer.

New method for cost-effective genome-wide DNA methylation analysis

Dr Chunxiao Song’s team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.

Using Herpesvirus to fight cancer

The Seymour lab at the Department of Oncology, University of Oxford, has published a new paper investigating the use of oncolytic herpes virus-1 as a vector to augment immunotherapy in cancer

State-of-the-art robots to improve Oxford cancer care

Oxford University Hospitals NHS Foundation Trust has purchased two new surgical robots that will greatly enhance the treatment that can be offered to patients, especially those with cancer.

Oxford success at the early detection sandpit on pancreatic cancer

Professor Eric O’Neill and Dr Pui San Tan receive funding as part of teams applying novel approaches for the early detection of pancreatic cancer.

Novel imaging device enters first round of development funding programme

Anna Vella is designing CAPULET: a device to increase the accuracy in delivering particle beam radiotherapy in cancer treatment

Oxford spin out influencing patient care world wide

Oxford cancer research spin our Optellum has received FDA clearance for the world’s first AI-powered clinical decision support for early lung cancer diagnosis

New partnership enables access to state-of-the-art radiotherapy machine

University of Oxford, OUH and GenesisCare have partnered to provide access to a new ViewRay MRIdian machine. It is the first of its kind in the UK and will help to improve challenging cancer treatment through faster, tailored radiotherapy.

Developing a system to simultaneously detect genetic and epigenetic information

Dr Benjamin Schuster-Böckler wins funding to develop algorithms that can identify both genetic variation and DNA methylation from the same sequencing data, with applications in biomedical research and detection of diseases such as cancer.

New Oxford technology assesses cancer patient vulnerability to COVID-19

New research from Prof Julia Hippisley-Cox has resulted in thousands of cancer patients being given prioritised access to the COVID-19 vaccine.

Detecting for multiple cancers in one simple test

Prof. Jason Davis is working alongside clinicians to introduce his biomarker assays into the clinic. Using a range of electroanalytical methods, together with electrode arrays and microfluidics, the platform has the potential to test for many types of cancers all at once, and at an earlier, pre-symptomatic stage.

Load More